EVT.DE
Price:
$8.5
Market Cap:
$1.51B
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company wa...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
1999-11-12
Stock Exchange
XETRA
Ticker
EVT.DE
According to Evotec SE’s latest financial reports and current stock price. The company's current PE Ratio is -8.85. This represents a change of -69.01% compared to the average of -28.56 of the last 4 quarters.
The mean historical PE Ratio of Evotec SE over the last ten years is 91.76. The current -8.85 PE Ratio has changed -1064.42% with respect to the historical average. Over the past ten years (40 quarters), EVT.DE's PE Ratio was at its highest in in the December 2020 quarter at 2.84K. The PE Ratio was at its lowest in in the September 2020 quarter at -604.34.
Average
91.76
Median
33.03
Minimum
-69.24
Maximum
741.58
Discovering the peaks and valleys of Evotec SE PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 719.88%
Maximum Annual PE Ratio = 741.58
Minimum Annual Increase = -148.02%
Minimum Annual PE Ratio = -69.24
Year | PE Ratio | Change |
---|---|---|
2023 | -44.87 | 192.31% |
2022 | -15.35 | -146.77% |
2021 | 32.82 | -95.57% |
2020 | 741.58 | 719.88% |
2019 | 90.45 | 183.01% |
2018 | 31.96 | -60.66% |
2017 | 81.24 | 126.87% |
2016 | 35.81 | 7.71% |
2015 | 33.25 | -148.02% |
2014 | -69.24 | 295.85% |
The current PE Ratio of Evotec SE (EVT.DE) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-9.13
5-year avg
160.93
10-year avg
91.76
Evotec SE’s PE Ratio is less than MorphoSys AG (-5.50), less than AIXTRON SE (14.91), less than Carl Zeiss Meditec AG (25.06), less than Bechtle AG (15.41), less than Qiagen N.V. (132.75),
Company | PE Ratio | Market cap |
---|---|---|
-5.50 | $2.53B | |
14.91 | $1.71B | |
25.06 | $5.08B | |
15.41 | $4.02B | |
132.75 | $8.86B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Evotec SE using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Evotec SE or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Evotec SE's PE Ratio?
How is the PE Ratio calculated for Evotec SE (EVT.DE)?
What is the highest PE Ratio for Evotec SE (EVT.DE)?
What is the 3-year average PE Ratio for Evotec SE (EVT.DE)?
What is the 5-year average PE Ratio for Evotec SE (EVT.DE)?
How does the current PE Ratio for Evotec SE (EVT.DE) compare to its historical average?